Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study
Ihr Browser zeigt an, ob sie diesen Verweis schon einmal besucht haben.
Vijiaratnam, Nirosen; Girges, Christine; Auld, Grace; Chau, Marisa; Maclagan, Kate; King, Alexa; Skene, Simon; Chowdhury, Kashfia; Hibbert, Steve; Morris, Huw; Limousin, Patricia; Athauda, Dilan; Carroll, Camille B; Hu, Michele T; Silverdale, Monty; Duncan, Gordon W; Chaudhuri, Ray; Lo, Christine; Del Din, Silvia; Yarnall, Alison J; Rochester, Lynn; Gibson, Rachel; Dickson, John; Hunter, Rachael; Libri, Vincenzo; Foltynie, Thomas
–
2021